TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.

TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …

TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.

TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…

TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment

TS-039545 — Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery

TS-037876 — A new method to produce RNA and RNA nanoparticles by using rolling circle transcription to produce RNA on a large scale.

TS-037840 — Amino esters nanomaterials for gene therapy and drug delivery.

TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.